IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL

Chemoresistance is a key obstacle in the clinical treatment and management of activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL), which leads to the poor prognosis of patients. Exploring novel biomarkers to early warn drug resistance and ameliorate the patients' outcome in ABC-DLBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Han-Bing, Wang, Di, Zhang, Yue, Shen, Di, Che, Yi-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845052/
https://www.ncbi.nlm.nih.gov/pubmed/36660244
http://dx.doi.org/10.1155/2023/1388041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845052/
https://www.ncbi.nlm.nih.gov/pubmed/36660244
http://dx.doi.org/10.1155/2023/1388041

Ejemplares similares